𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dopaminagonists and fibrotic valvular heart disease: Further considerations

✍ Scribed by Olivier Rascol; Atul Pathak; Haleh Bagheri; Jean-Louis Montastruc

Book ID
102504047
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
61 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Companion letters have been published in this issue of Movement Disorders: Chaudhuri et al., pp 1522–1523, and Horowski et al., pp 1523–1524.

πŸ“œ SIMILAR VOLUMES

Endothelium and valvular diseases of the
Endothelium and valvular diseases of the heart
✍ Richard L. Leask; Neelesh Jain; Jagdish Butany πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 818 KB

## Abstract It has become increasingly evident that the endothelium plays a critical role in the pathogenesis of valvular heart disease. The endothelium helps regulate vascular tone, inflammation, thrombosis, and vascular remodeling. Dysfunction of the endothelial cells has been linked to many vasc

Bromocriptine use and the risk of valvul
Bromocriptine use and the risk of valvular heart disease
✍ Louis C.S. Tan; Kenneth K.C. Ng; Wing-Lok Au; Raymond K.K. Lee; Yiong-Huak Chan; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 68 KB

## Abstract It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot‐derived dopamine agonist (DA) with partial 5‐HT~2B~ activity, is associated with a similar risk. We assessed the frequ